The Covid-19 pandemic gave big pharma big payday. But it also caused the industry to rethink a globalized supply chain centered on Asia. What will it take to reshore at least some generic drugs to the U.S.
Can the U.S. really bring manufacturing home? A McKinsey study shows that existing concentration of some supply chains will make it hard. Here’s what needs to be done.
Arizona gets $60 million solar plant. But the owner is China’s JA Solar, a company that will be in the cross hairs of forced labor laws.
By Charles Benoit, CPA Trade Counsel In December, the U.S.-China Commission, a group created by Congress to advise on managing the bilateral relationship, formally recommended
Canadian Solar is mostly Chinese-run and produced. Its solar panels in a Maine government project may be tainted by forced labor.
A Department of Energy official warns that China’s outsized role in the solar industry is a headwind for Biden’s green energy plans, and energy security.
The November trade deficit fell, but that didn’t stop the U.S. from record imports this year. The goods deficit is now over $1.1 trillion.
A Senate Commerce subcommittee hearing heard from witnesses who said worker shortages will ultimately be a drag on U.S. reshoring efforts. Pharmaceutical reps warned of high energy costs, which could add to import dependence.
Ambassador Bob Lighthizer, the former U.S. Trade Representative in the Trump administration, joined Laura Ingraham on Fox News Channel to discuss trade, the TPP, and
One of India’s pharmaceutical labs has run afoul of the FDA many times this year. The U.S. is dependent on foreign labs like Aurobindo for its drug supply. Can the government help change that?
